FDA Approves Marketing Of Plant-Derived Marijuana Medicine

GW Pharmaceuticals Epidiolex

DISTRICT OF COLUMBIA:  Regulators at the US Food and Drug Administration on Monday granted market approval to Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD) for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. The proprietary extract formulation – developed by the British biotechnology firm GW Pharmaceuticals – had Read the full article…

FDA Approves First Cannabis-Based Epilepsy Drug

fda-logo

MARYLAND: The U.S. Food and Drug Administration has approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from Read the full article…

Study: CBD Extracts Significantly Reduced Seizure Frequency In Children With Refractory Epilepsy

Israeli researchers assessed the sustained daily use of extracted CBD oils in a cohort of young patients with treatment resistant epilepsy.

ISRAEL: The adjunctive use of CBD extracts is safe and effective in adolescent patients with refractory epilepsy, according to clinical data published online ahead of print in the journal Brain & Development. Israeli researchers assessed the sustained daily use of extracted CBD oils in a cohort of young patients with treatment resistant epilepsy. Thirty-five percent of participants experienced a Read the full article…

FDA Grants ‘Priority Review’ Of Plant-Derived CBD Extract

If Epidiolex achieves FDA-approval, analysts suggest the product could retail for between $30,000 to $60,000 annually.

DISTRICT OF COLUMBIA: Representatives of the US Food and Drug Administration will undertake a ‘priority review‘ of data specific to the safety and efficacy of Epidiolex, a standardized, plant-derived CBD extract formulated by a British pharmaceutical company. The review is scheduled to be completed by June 27, 2018. Phase III clinical trial data shows that Epidiolex Read the full article…

Study Confirms Safety Of Cannabis Drug CBD

An early American study has assessed the safety of a drug made from a compound derived from cannabis.

NEW YORK:  Using a drug based on a chemical found in the cannabis plant to treat epilepsy has been controversial to say the least. An early study from the US may lend more weight to its scientific standing, however. The study suggests that the drug is safe, well-tolerated and effective. An early American study has Read the full article…

Georgia Boy Among First To Receive Experimental Medical Marijuana Drug

A 7-year-old boy is one of the first people in the country to receive a potent form of medical marijuana as part of a clinical trial to reduce seizures.

GEORGIA:  A 7-year-old boy is one of the first people in the country to receive a potent form of medical marijuana as part of an “extended use” clinical trial to reduce seizures. Preston Weaver, who lives in Athens, Georgia, has Lennox-Gastaut syndrome which is a severe form of epilepsy. He experiences up to 100 seizures a day, although many are Read the full article…

GW Pharmaceuticals Closes U.S. Public Offering; Cannabis-Based Medicines Progress

Cannabis-based medicines progress.

NORTH CAROLINA:  Yesterday, Salisbury, UK-based GW Pharmaceuticals plc announced the closing of its public offering of 1.7 million American Depositary Shares on the NASDAQ Global Market. When taken together with the full exercise of options for another 255,000 ADSs by the underwriters at $86.83/ADS, the offering totaled $169.8 million. Although some of the ADRs were sold by Read the full article…

NY State To Hold Clinical Trials For Marijuana

An agreement was signed Sunday between Gov. Andrew Cuomo’s administration and GW Pharmaceuticals. The state Health Department and the company will develop the framework for a clinical trial for a marijuana-based drug for people under the age of 18.

NEW YORK: New York State is partnering with a British company to hold clinical trials for marijuana-based medication for children who have seizures that are resistant to their medicine. An agreement was signed Sunday between Gov. Andrew Cuomo’s administration and GW Pharmaceuticals. The state Health Department and the company will develop the framework for a Read the full article…

FDA-Approved Medical Marijuana Clinical Trial Gets Underway Next Month For Kids With Epilepsy

Meghan Wilson holds the marijuana they just obtained as her husband Brian gets their 2 year old daughter Vivian ready to go outside the Compassionate Care Foundation, New Jersey's 2nd medical marijuana dispensary.

NEW JERSEY: A nationally renowned pediatric neurologist at Saint Barnabas has gotten FDA approval to study whether a cannabis-based drug could prevent seizures in children diagnosed with severe forms of epilepsy. The development is sure to be watched closely in New Jersey, where a number of families whose children have Dravet syndrome, a potentially deadly form Read the full article…

FDA Approves Clinical Trials For Cannabis-based Epilepsy Drug

On Oct.  4, at the NYU Langone Medical Center, Devinsky led a conference entitled, "Cannabidiols: Potential Use in Epilepsy & Other Neurological Disorders." During the affair, Devinsky and Cilio led a presentation on planned trials on CBD in children with treatment resistant epilepsy.

DISTRICT OF COLUMBIA: The U.S.  Food and Drug Administration has approved clinical trials of a cannabis-based drug and its effects on epilepsy.  The treatment, Epidiolex, is 98 percent purified cannabidiol ( CBD ) made by GW Pharmaceuticals based out of the U.K. There are around 60 known chemicals contained in cannabis called cannabinoids.  Tetrahydrocannabinol, also known Read the full article…